Watermelon Jello Shot The Watermelon Jello Shot combines coconut rum and watermelon jello for a sweet, fruity, and fun party treat that's sure to be a crowd-pleaser
For patients requiring additional glycemic lowering, the dose can be further up-titrated to 14 mg once daily after taking the 7 mg dose for at least 30 days
Early cardiovascular outcome trials of GLP-1RAs for diabetes included secondary kidney endpoints, typically defined by a 5-point composite renal outcome (CRO): increased urinary albumin-to-creatinine ratio, new-onset macroalbuminuria, sustained decline in estimated glomerular filtration rate (eGFR), initiation of chronic renal replacement therapy, and renal death.[15, 16] In patients with T2DM, GLP-1RAs significantly reduced CRO incidence, primarily driven by an 18% reduction in new-onset macroalbuminuria.[47] More recently, the FLOW trial, a dedicated kidney outcome trial in patients with T2DM and CKD, was terminated early due to overwhelming efficacy and mortality benefit.[24] FLOW revealed that semaglutide reduced the risk of a composite kidney outcome by 24% compared to placebo.[24] Emerging data suggest GLP-1RAs may also offer kidney benefits in populations without diabetes.[48] The SELECT trial demonstrated a reduced risk of persistent eGFR decline in patients with obesity and cardiovascular disease treated with semaglutide.[15] Additionally, a meta-analysis of placebo-controlled RCTs reported a slower decline in eGFR over one year in individuals with a baseline eGFR 3060 mL/min/1.73m 2 treated with GLP-1RAs regardless of diabetes status.[12] These findings support the potential utility of GLP-1RAs in CKD patients without diabetes, and additional dedicated trials are underway to validate these outcomes in populations without diabetes
doi: 10.1016/j.ajog.2005.06.015 158 DuksalFKilicITufanACAkdoganI
More than half of semaglutide users experience minimal to no nausea, especially when following proper dose escalation protocols
We had to Google the policy to confirm how it worked
